Search Results - "Bundy, Brian"

Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals by Sims, Emily K, Bundy, Brian N, Stier, Kenneth, Serti, Elisavet, Lim, Noha, Long, S Alice, Geyer, Susan M, Moran, Antoinette, Greenbaum, Carla J, Evans-Molina, Carmella, Herold, Kevan C

“…We analyzed the effects of a single 14-day course of teplizumab treatment on metabolic function and immune cells among participants in a previously reported…”
Get more information

An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes by Herold, Kevan C, Bundy, Brian N, Long, S. Alice, Bluestone, Jeffrey A, DiMeglio, Linda A, Dufort, Matthew J, Gitelman, Stephen E, Gottlieb, Peter A, Krischer, Jeffrey P, Linsley, Peter S, Marks, Jennifer B, Moore, Wayne, Moran, Antoinette, Rodriguez, Henry, Russell, William E, Schatz, Desmond, Skyler, Jay S, Tsalikian, Eva, Wherrett, Diane K, Ziegler, Anette-Gabriele, Greenbaum, Carla J

“…In this trial, high-risk nondiabetic relatives of patients with type 1 diabetes were randomly assigned to receive teplizumab (an anti-CD3 monoclonal antibody)…”
Get full text

Changing the landscape for type 1 diabetes: the first step to prevention by Dayan, Colin M, Korah, Maria, Tatovic, Danijela, Bundy, Brian N, Herold, Kevan C

“…Over several decades, studies have described the progression of autoimmune diabetes, from the first appearance of autoantibodies until, and after, the…”
Get full text

C-Peptide Levels in Subjects Followed Longitudinally Before and After Type 1 Diabetes Diagnosis in TrialNet by Bogun, Magdalena M, Bundy, Brian N, Goland, Robin S, Greenbaum, Carla J

“…Insulin secretion declines rapidly after diagnosis of type 1 diabetes, followed by a slower rate of change. Previous studies have demonstrated that the…”
Get full text

A model-based approach to sample size estimation in recent onset type 1 diabetes by Bundy, Brian N., Krischer, Jeffrey P.

“…Background The area under the curve C‐peptide following a 2‐h mixed meal tolerance test from 498 individuals enrolled on five prior TrialNet studies of recent…”
Get full text

Teplizumab in Relatives at Risk for Type 1 Diabetes. Reply by Herold, Kevan C, Bundy, Brian N, Krischer, Jeffrey P

Get full text

Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes by Haller, Michael J., Schatz, Desmond A., Skyler, Jay S., Krischer, Jeffrey P., Bundy, Brian N., Miller, Jessica L., Atkinson, Mark A., Becker, Dorothy J., Baidal, David, DiMeglio, Linda A., Gitelman, Stephen E., Goland, Robin, Gottlieb, Peter A., Herold, Kevan C., Marks, Jennifer B., Moran, Antoinette, Rodriguez, Henry, Russell, William, Wilson, Darrell M., Greenbaum, Carla J., Greenbaum, C., Atkinson, M., Baidal, D., Battaglia, M., Becker, D., Bingley, P., Bosi, E., Buckner, J., Clements, M., Colman, P., DiMeglio, L., Evans-Molina, C., Gitelman, S., Goland, R., Gottlieb, P., Herold, K., Knip, M., Krischer, J., Lernmark, A., Moore, W., Moran, A., Muir, A., Palmer, J., Peakman, M., Philipson, L., Raskin, P., Redondo, M., Rodriguez, H., Russell, W., Spain, L., Schatz, D.A., Sosenko, J., Wherrett, D., Wilson, D., Winter, W., Ziegler, A., Anderson, M., Antinozzi, P., Benoist, C., Blum, J., Bourcier, K., Chase, P., Clare-Salzler, M., Clynes, R., Cowie, C., Eisenbarth, G., Fathman, C.G., Grave, G., Harrison, L., Hering, B., Insel, R., Jordan, S., Kaufman, F., Kay, T., Kenyon, N., Klines, R., Lachin, J., Leschek, E., Mahon, J., Marks, J.B., Monzavi, R., Nanto-Salonen, K., Nepom, G., Orban, T., Parkman, R., Pescovitz, M., Peyman, J., Pugliese, A., Ridge, J., Roep, B., Roncarolo, M., Savage, P., Simell, O., Sherwin, R., Siegelman, M., Skyler, J.S., Steck, A., Thomas, J., Trucco, M., Wagner, J.

“…OBJECTIVE A pilot study suggested that combination therapy with low-dose anti-thymocyte globulin (ATG) and pegylated granulocyte colony-stimulating factor…”
Get full text

Index60 Is Superior to HbA1c for Identifying Individuals at High Risk for Type 1 Diabetes by Jacobsen, Laura M, Bundy, Brian N, Ismail, Heba M, Clements, Mark, Warnock, Megan, Geyer, Susan, Schatz, Desmond A, Sosenko, Jay M

“…HbA1c from ≥ 5.7% to < 6.5% (39-46 mmol/mol) indicates prediabetes according to American Diabetes Association guidelines, yet its identification of prediabetes…”
Get full text

Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study by Ozols, Robert F, Bundy, Brian N, Greer, Benjamin E, Fowler, Jeffrey M, Clarke-Pearson, Daniel, Burger, Robert A, Mannel, Robert S, DeGeest, Koen, Hartenbach, Ellen M, Baergen, Rebecca

“…In randomized trials the combination of cisplatin and paclitaxel was superior to cisplatin and cyclophosphamide in advanced-stage epithelial ovarian cancer…”
Get full text

Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial by Orban, Tihamer, MD, Bundy, Brian, PhD, Becker, Dorothy J, Prof, DiMeglio, Linda A, MD, Gitelman, Stephen E, Prof, Goland, Robin, Prof, Gottlieb, Peter A, Prof, Greenbaum, Carla J, MD, Marks, Jennifer B, Prof, Monzavi, Roshanak, MD, Moran, Antoinette, Prof, Raskin, Philip, Prof, Rodriguez, Henry, Prof, Russell, William E, Prof, Schatz, Desmond, Prof, Wherrett, Diane, MD, Wilson, Darrell M, Prof, Krischer, Jeffrey P, Prof, Skyler, Jay S, Dr, Prof

“…Summary Background The immunopathogenesis of type 1 diabetes mellitus is associated with T-cell autoimmunity. To be fully active, immune T cells need a…”
Get full text

Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials by Moran, Antoinette, Prof, Bundy, Brian, PhD, Becker, Dorothy J, Prof, DiMeglio, Linda A, MD, Gitelman, Stephen E, Prof, Goland, Robin, Prof, Greenbaum, Carla J, MD, Herold, Kevan C, Prof, Marks, Jennifer B, Prof, Raskin, Philip, Prof, Sanda, Srinath, MD, Schatz, Desmond, Prof, Wherrett, Diane K, MD, Wilson, Darrell M, Prof, Krischer, Jeffrey P, Prof, Skyler, Jay S, Prof, Pickersgill, Linda, MD, de Koning, Eelco, Prof, Ziegler, Anette-G, Prof, Böehm, Bernhard, Prof, Badenhoop, Klaus, Prof, Schloot, Nanette, MD, Bak, Jens Friis, MD, Pozzilli, Paolo, Prof, Mauricio, Didac, MD, Donath, Marc Y, Prof, Castaño, Luis, Prof, Wägner, Ana, MD, Lervang, Hans Henrik, MD, Perrild, Hans, MD, Mandrup-Poulsen, Thomas, Prof

“…Summary Background Innate immunity contributes to the pathogenesis of autoimmune diseases, such as type 1 diabetes, but until now no randomised, controlled…”
Get full text

Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial by Russell, William E, Bundy, Brian N, Anderson, Mark S, Cooney, Laura A, Gitelman, Stephen E, Goland, Robin S, Gottlieb, Peter A, Greenbaum, Carla J, Haller, Michael J, Krischer, Jeffrey P, Libman, Ingrid M, Linsley, Peter S, Long, S Alice, Lord, Sandra M, Moore, Daniel J, Moore, Wayne V, Moran, Antoinette M, Muir, Andrew B, Raskin, Philip, Skyler, Jay S, Wentworth, John M, Wherrett, Diane K, Wilson, Darrell M, Ziegler, Anette-Gabriele, Herold, Kevan C

“…Previous studies showed that inhibiting lymphocyte costimulation reduces declining β-cell function in individuals newly diagnosed with type 1 diabetes. We…”
Get full text

Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study by OZOLS, Robert F, BUNDY, Brian N, GREER, Benjamin E, FOWLER, Jeffrey M, CLARKE-PEARSON, Daniel, BURGER, Robert A, MANNEL, Robert S, DEGEEST, Koen, HARTENBACH, Ellen M, BAERGEN, Rebecca

“…In randomized trials the combination of cisplatin and paclitaxel was superior to cisplatin and cyclophosphamide in advanced-stage epithelial ovarian cancer…”
Get full text

Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer by Armstrong, Deborah K, Bundy, Brian, Wenzel, Lari, Huang, Helen Q, Baergen, Rebecca, Lele, Shashikant, Copeland, Larry J, Walker, Joan L, Burger, Robert A

“…In a trial of adjuvant chemotherapy for ovarian cancer, a regimen of intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel was superior to…”
Get full text

Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial by Gitelman, Stephen E, Bundy, Brian N, Ferrannini, Ele, Lim, Noha, Blanchfield, J Lori, DiMeglio, Linda A, Felner, Eric I, Gaglia, Jason L, Gottlieb, Peter A, Long, S Alice, Mari, Andrea, Mirmira, Raghavendra G, Raskin, Philip, Sanda, Srinath, Tsalikian, Eva, Wentworth, John M, Willi, Steven M, Krischer, Jeffrey P, Bluestone, Jeffrey A, Barr, Mayalin, Blanchfield, J Lori, Bluestone, Jeffrey A, Buchanan, Jeanne, Bundy, Brian N, Cabbage, Joanne, Coleman, Peter, De La Vega, Monica, DiMeglio, Linda A, Evans-Molina, Carmella, Felner, Eric I, Ferrannini, Ele, Ferrara, Christine, Gaglia, Jason L, Gitelman, Stephen E, Gottlieb, Peter A, Healy, Felicity, Higgins, Laurie, Hildinger, Megan, Jenkins, Margaret, Kayton Bryant, Nora, Kinderman, Amanda, Koshy, Nisha, Kost, Brianne, Krischer, Jeffrey P, Krishfield, Suzanne, Kucheruk, Olena, Lim, Noha, Lindsley, Karen, Long, S Alice, Mantravadi, Manasa, Mari, Andrea, Mesfin, Shelley, Michels, Aaron, Migre, Mary Ellen, Minnock, Pantea, Mirmira, Raghavendra G, Mohammed-Nur, Elham, Nelson, Jennifer, Nursing, Ashvin, O'Donnell, Ryan, Olivos, Diana, Parker, Melissa, Raskin, Philip, Redl, Leanne, Reed, Nicole, Resnick, Brittany, Sanda, Srinath, Sayre, Peter, Serti, Elisavet, Sims, Emily, Smith, Karen, Soppe, Carol, Stuart, Fiona, Szubowicz, Sarah, Tansey, Michel, Terrell, Jennifer, Tersey, Sarah, Torok, Christine, Tsalikian, Eva, Watson, Kelly, Wentworth, John M, Wesch, Rebecca, Willi, Steven, Woerner, Stephanie

“…Type 1 diabetes results from autoimmune-mediated destruction of β cells. The tyrosine kinase inhibitor imatinib might affect relevant immunological and…”
Get full text

Randomized Phase III Trial of Cisplatin With or Without Topotecan in Carcinoma of the Uterine Cervix: A Gynecologic Oncology Group Study by LONG, Harry J, BUNDY, Brian N, GRENDYS, Edward C, BENDA, Jo Ann, MCMEEKIN, D. Scott, SOROSKY, Joel, MILLER, David S, EATON, Lynne A, FIORICA, James V

“…On the basis of reported activity of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) or topotecan plus cisplatin in advanced cervix cancer, we…”
Get full text

Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial by Wherrett, Diane K, MD, Bundy, Brian, PhD, Becker, Dorothy J, Prof, DiMeglio, Linda A, MD, Gitelman, Stephen E, Prof, Goland, Robin, Prof, Gottlieb, Peter A, Prof, Greenbaum, Carla J, MD, Herold, Kevan C, Prof, Marks, Jennifer B, Prof, Monzavi, Roshanak, MD, Moran, Antoinette, Prof, Orban, Tihamer, MD, Palmer, Jerry P, MD, Raskin, Philip, Prof, Rodriguez, Henry, Prof, Schatz, Desmond, Prof, Wilson, Darrell M, Prof, Krischer, Jeffrey P, Prof, Skyler, Jay S, Dr, Prof

“…Summary Background Glutamic acid decarboxylase (GAD) is a major target of the autoimmune response that occurs in type 1 diabetes mellitus. In animal models of…”
Get full text

Episodic ataxia type 1: clinical characterization, quality of life and genotype-phenotype correlation by GRAVES, Tracey D, CHA, Yoon-Hee, HAHN, Angelika F, BAROHN, Richard, SALAJEGHEH, Mohammed K, GRIGGS, Robert C, BUNDY, Brian N, JEN, Joanna C, BALOH, Robert W, HANNA, Michael G

“…Episodic ataxia type 1 is considered a rare neuronal ion channel disorder characterized by brief attacks of unsteadiness and dizziness with persistent…”
Get full text

Early Metabolic Endpoints Identify Persistent Treatment Efficacy in Recent-Onset Type 1 Diabetes Immunotherapy Trials by Jacobsen, Laura M, Cuthbertson, David, Bundy, Brian N, Atkinson, Mark A, Moore, Wayne, Haller, Michael J, Russell, William E, Gitelman, Stephen E, Herold, Kevan C, Redondo, Maria J, Sims, Emily K, Wherrett, Diane K, Moran, Antoinette, Pugliese, Alberto, Gottlieb, Peter A, Sosenko, Jay M, Ismail, Heba M

“…Mixed-meal tolerance test-stimulated area under the curve (AUC) C-peptide at 12-24 months represents the primary end point for nearly all intervention trials…”
Get full text

Intraepithelial CD8+ Tumor-Infiltrating Lymphocytes and a High $CD8^+/regulatory$ T Cell Ratio Are Associated with Favorable Prognosis in Ovarian Cancer by Sato, Eiichi, Olson, Sara H., Jiyoung Ahn, Brian Bundy, Nishikawa, Hiroyoshi, Qian, Feng, Jungbluth, Achim A., Denise Frosina, Gnjatic, Sacha, Christine Ambrosone, Kepner, James, Tosin Odunsi, Ritter, Gerd, Shashikant Lele, Chen, Yao-Tseng, Haruo Ohtani, Old, Lloyd J., Odunsi, Kunle

“…In a recent report, [Zhang et al. (2003) N. Engl. J. Med. 348,203-213], the presence of CD3+ tumor-infiltrating lymphocytes (TILs) was found to correlate with…”
Get full text